Cargando…

Natural variation of HIV-1 group M integrase: Implications for a new class of antiretroviral inhibitors

HIV-1 integrase is the third enzymatic target of antiretroviral (ARV) therapy. However, few data have been published on the distribution of naturally occurring amino acid variation in this enzyme. We therefore characterized the distribution of integrase variants among more than 1,800 published group...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rhee, Soo-Yon, Liu, Tommy F, Kiuchi, Mark, Zioni, Rafael, Gifford, Robert J, Holmes, Susan P, Shafer, Robert W
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2546438/ https://www.ncbi.nlm.nih.gov/pubmed/18687142 http://dx.doi.org/10.1186/1742-4690-5-74

Ejemplares similares

HIV-1 Integrase Inhibitor Resistance and Its Clinical Implications
por: Blanco, Jose-Luis, et al.
Publicado: (2011)

HIV-1 Protease, Reverse Transcriptase, and Integrase Variation
por: Rhee, Soo-Yon, et al.
Publicado: (2016)

The calibrated population resistance tool: standardized genotypic estimation of transmitted HIV-1 drug resistance
por: Gifford, Robert J., et al.
Publicado: (2009)

HIV-1 Subtype B Protease and Reverse Transcriptase Amino Acid Covariation
por: Rhee, Soo-Yon, et al.
Publicado: (2007)

Geographically-stratified HIV-1 group M pol subtype and circulating recombinant form sequences
por: Rhee, Soo-Yon, et al.
Publicado: (2018)

Treatment Emergent Dolutegravir Resistance Mutations in Individuals Naïve to HIV-1 Integrase Inhibitors: A Rapid Scoping Review
por: Tao, Kaiming, et al.
Publicado: (2023)

Adherence to contemporary antiretroviral treatment regimens and impact on immunological and virologic outcomes in a US healthcare system
por: T. Tchakoute, Christophe, et al.
Publicado: (2022)

HIV-1 Group M Capsid Amino Acid Variability: Implications for Sequence Quality Control of Genotypic Resistance Testing
por: Tao, Kaiming, et al.
Publicado: (2023)

Selection analyses of paired HIV-1 gag and gp41 sequences obtained before and after antiretroviral therapy
por: Tzou, Philip L., et al.
Publicado: (2018)

Standardized representation, visualization and searchable repository of antiretroviral treatment-change episodes
por: Rhee, Soo-Yon, et al.
Publicado: (2012)

Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations
por: Reuman, Elizabeth C., et al.
Publicado: (2010)

HIV-2 Integrase Variation in Integrase Inhibitor-Naïve Adults in Senegal, West Africa
por: Gottlieb, Geoffrey S., et al.
Publicado: (2011)

Raltegravir: first in class HIV integrase inhibitor
por: Temesgen, Zelalem, et al.
Publicado: (2008)

Resistance to new antiretrovirals (ETV, anti-integrases, entry inhibitors)
por: Ceccherini-Silberstein, Francesca
Publicado: (2010)

Structural Implications of Genotypic Variations in HIV-1 Integrase From Diverse Subtypes
por: Rogers, Leonard, et al.
Publicado: (2018)

Temporal Trends in HIV-1 Mutations Used for the Surveillance of Transmitted Drug Resistance
por: Rhee, Soo-Yon, et al.
Publicado: (2021)

Virological Failure and Acquired Genotypic Resistance Associated With Contemporary Antiretroviral Treatment Regimens
por: Rhee, Soo-Yon, et al.
Publicado: (2020)

Response to Therapy in Antiretroviral Therapy–Naive Patients With Isolated Nonnucleoside Reverse Transcriptase Inhibitor–Associated Transmitted Drug Resistance
por: Clutter, Dana S., et al.
Publicado: (2016)

Costly Class-1 integrons and the domestication of the the functional integrase
por: Harms, Klaus, et al.
Publicado: (2013)

HIV integrase variability and genetic barrier in antiretroviral naïve and experienced patients
por: Piralla, Antonio, et al.
Publicado: (2011)

HIV-1 integrase polymorphisms are associated with prior antiretroviral drug exposure
por: van Hal, Sebastiaan J, et al.
Publicado: (2009)

More effective drugs lead to harder selective sweeps in the evolution of drug resistance in HIV-1
por: Feder, Alison F, et al.
Publicado: (2016)

Correction: More effective drugs lead to harder selective sweeps in the evolution of drug resistance in HIV-1
por: Feder, Alison F, et al.
Publicado: (2017)

Genetic Variability of HIV-1 for Drug Resistance Assay Development
por: Clutter, Dana S., et al.
Publicado: (2016)

Activation of class 1 integron integrase is promoted in the intestinal environment
por: Baltazar, Murielle, et al.
Publicado: (2022)

Development of Elvitegravir Resistance and Linkage of Integrase Inhibitor Mutations with Protease and Reverse Transcriptase Resistance Mutations
por: Winters, Mark A., et al.
Publicado: (2012)

Risk of immune reconstitution inflammatory syndrome with integrase inhibitors versus other classes of antiretrovirals: a systematic review and meta-analysis of randomised trials
por: Zhao, Ying, et al.
Publicado: (2022)

Choice of the initial antiretroviral treatment for HIV-positive individuals in the era of integrase inhibitors
por: Alejos, Belén, et al.
Publicado: (2019)

A New Class of Multimerization Selective Inhibitors of HIV-1 Integrase
por: Sharma, Amit, et al.
Publicado: (2014)

Q148N, a Novel Integrase Inhibitor Resistance Mutation Associated with Low-Level Reduction in Elvitegravir Susceptibility
por: Varghese, Vici, et al.
Publicado: (2016)

HIV/HCV-coinfection: which role can new antiretrovirals such as integrase inhibitors play?
por: Vogel, Martin, et al.
Publicado: (2009)

The impact of integrase inhibitors on steatosis and fibrosis biomarkers in persons with HIV naïve to antiretroviral therapy
por: Fernandes, Sara Rodrigues, et al.
Publicado: (2023)

Characterization of natural polymorphic sites of the HIV-1 integrase before the introduction of HIV-1 integrase inhibitors in Germany
por: Meixenberger, Karolin, et al.
Publicado: (2014)

A multifaceted analysis of HIV-1 protease multidrug resistance phenotypes
por: Doherty, Kathleen M, et al.
Publicado: (2011)

Using the class 1 integron-integrase gene as a proxy for anthropogenic pollution
por: Gillings, Michael R, et al.
Publicado: (2015)

A targeted DNA substrate mechanism for the inhibition of HIV‐1 integrase by inhibitors with antiretroviral activity
por: Ammar, Farah F., et al.
Publicado: (2016)

Altered adipose tissue macrophage populations in people with HIV on integrase inhibitor-containing antiretroviral therapy
por: Vakili, Sarah, et al.
Publicado: (2022)

Trends in Genotypic HIV-1 Antiretroviral Resistance between 2006 and 2012 in South African Patients Receiving First- and Second-Line Antiretroviral Treatment Regimens
por: Van Zyl, Gert U., et al.
Publicado: (2013)

Integrase and integration: biochemical activities of HIV-1 integrase
por: Delelis, Olivier, et al.
Publicado: (2008)

HIV-1 Antiretroviral Resistance: Scientific Principles and Clinical Applications
por: Tang, Michele W., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_3239lrtcel3inlsubvk0ea09v4